Drug intelligence / Profile preview

Carminal

Development stage: Unknown
Lead developer: Laboratorios Catalysis
Administration: Oral

Overview

Carminal is an oral liquid herbal supplement developed by Laboratorios Catalysis, S.L., specifically formulated to support the treatment of *Helicobacter pylori*-associated gastritis. The product utilizes a proprietary Molecular Activation Technology (MAT) to enhance the biological activity and antioxidant capacity of its ingredients, the primary of which is *Aloe vera* extract. Carminal is designed to exert anti-inflammatory, immunomodulatory, and cytoprotective effects on the gastric mucosa. It is currently being evaluated in clinical trials (such as NCT07179237) as an adjunct to standard *H. pylori* eradication therapy to improve bacterial clearance rates, accelerate the healing of the gastric lining, and mitigate symptoms associated with gastric inflammation.

Brand names: Carminal
Other names: Carminal Oral Solution

Beyond the preview

Go deeper on Carminal.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carminal.

Explore the full profile